Use of phenytoin in the prevention of motion sickness.
In a placebo-controlled double-blind crossover pilot study of acute Coriolis-induced motion sickness treatment/prevention in humans employing an anticonvulsant dose of phenytoin, a mean increase in tolerance to motion stress from 4.87 min (S.D. = 5.55) to 46.87 min (S.D. = 32.6) was obtained. This represents a greater than fourfold improvement in efficacy over any currently available single agent and is more than twice as effective as the scopolamine/dexadrine combination. There were none of the usual side effects of blurred vision, dizziness, dry mouth, or sedation.
Chelen
W
W
Air Force Institute of Technology, Wright-Patterson AFB, Dayton, OH 45433.
Kabrisky
M
M
Hatsell
C
C
Morales
R
R
Fix
E
E
Scott
M
M
D000284:Administration, Oral; D000328:Adult; D003312:Coriolis Force; D004311:Double-Blind Method; D004569:Electroencephalography; D006801:Humans; D008297:Male; D009041:Motion Sickness / Q000188:drug therapy* / Q000503:physiopathology; D010672:Phenytoin / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D010865:Pilot Projects
D010672:Phenytoin